Representing Fearless andUndaunted Innovators.

Wilson Sonsini represents the fearless and forward-looking—the undaunted innovators and investors who are launching breakthrough products and services.

The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.

For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us

Quick Links

Wilson Sonsini secured a jury trial win for Google in a case alleging misuse of advertising technology.

Click for additional details.

Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

News and Featured Insights

News Articles

Wilson Sonsini Attorneys Named to 2026 Lawdragon 500 Leading Energy Lawyers Guide

Alerts

FTC Conditions Aurobindo’s Acquisition of Lannett on Divestiture of Four Generic Drugs

News Articles

Wilson Sonsini Receives NLADA 2026 Beacon of Justice Award

Leading Matters

Client Highlights

Wilson Sonsini Advises Kai Health on $4.8 Million Seed Round

On June 29, 2026, Kai Health, an AI-powered performance improvement platform for emergency medicine, announced a $4.8 million seed round led by Distributed Ventures. Wilson Sonsini Goodrich & Rosati advised Kai Health on the transaction.

Learn More

Client Highlights

Wilson Sonsini Advises Adyen on Acquisition of Orb

Wilson Sonsini is pleased to have represented Adyen in its recently completed acquisition of Orb.

Learn More

Client Highlights

Wilson Sonsini Advises yes& on $3 Million Pre-Seed Financing

On June 23, 2026, yes&, a remix-native AI creative community platform, announced that it has raised $3 million in pre-seed funding, led by Accel with support from Parable. Wilson Sonsini Goodrich & Rosati advised yes& on the transaction.

Learn More

Client Highlights

Wilson Sonsini Advises Cognite, Major Shareholders on $3.1 Billion Sale to Schneider Electric

On June 30, 2026, Aker ASA (Aker) and the other shareholders of Cognite announced that they have entered into an agreement to sell 100 percent of the shares in Cognite Holding B.V. (Cognite) to Schneider Electric based on an enterprise value of US$3.1 billion. Wilson Sonsini Goodrich & Rosati’s cross-border tech M&A team advised Cognite and its major shareholders, including Aker, TCV, and Accel, on the transaction.

Learn More

Client Highlights

Wilson Sonsini Advises Rocket Lab on $8 Billion Acquisition of Iridium

On June 29, 2026, Rocket Lab Corporation, a global leader in launch and space systems, and Iridium Communications, a leading provider of global voice, data and positioning, navigation, and timing satellite services, announced they have entered into a definitive agreement under which Rocket Lab will acquire Iridium. Rocket Lab will acquire all the outstanding shares of Iridium common stock for $54 per share in a cash and stock transaction. This represents an enterprise value for Iridium of approximately $8 billion. Wilson Sonsini Goodrich & Rosati is advising Rocket Lab on the transaction.

Learn More

Client Highlights

Wilson Sonsini Advises Sail Research on $80 Million Series A

On June 25, 2026, Sail Research, an infrastructure company purpose-built for long-horizon AI agents, announced it has raised $80 million in seed and Series A funding at a $450 million valuation. The Series A was led by Kleiner Perkins, and the seed round was led by Sequoia. Other participating investors included Redpoint Ventures, Theory Ventures, Vine Ventures, CRV, A*, and Abstract Ventures, in addition to angel investors, including John Hennessy, chairman of Alphabet Inc., Lip-Bu Tan, CEO of Intel, and Tri Dao, Chief Scientist at Together AI. Wilson Sonsini Goodrich & Rosati advised Sail Research on the transaction.

Learn More

See More Leading Matters

The Life Sciences Report – June 2026

This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.